HomeCompareCMPI vs NNN

CMPI vs NNN: Dividend Comparison 2026

CMPI yields 19.05% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMPI wins by $43.3K in total portfolio value
10 years
CMPI
CMPI
● Live price
19.05%
Share price
$10.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.9K
Annual income
$6,079.53
Full CMPI calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — CMPI vs NNN

📍 CMPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMPINNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMPI + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMPI pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMPI
Annual income on $10K today (after 15% tax)
$1,619.05/yr
After 10yr DRIP, annual income (after tax)
$5,167.60/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, CMPI beats the other by $2,925.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMPI + NNN for your $10,000?

CMPI: 50%NNN: 50%
100% NNN50/50100% CMPI
Portfolio after 10yr
$47.2K
Annual income
$4,358.48/yr
Blended yield
9.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

CMPI
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMPI buys
0
NNN buys
0
No recent congressional trades found for CMPI or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMPINNN
Forward yield19.05%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$68.9K$25.6K
Annual income after 10y$6,079.53$2,637.42
Total dividends collected$38.2K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: CMPI vs NNN ($10,000, DRIP)

YearCMPI PortfolioCMPI Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$12,605$1,904.76$10,737$617.02+$1.9KCMPI
2$15,731$2,243.84$11,577$710.93+$4.2KCMPI
3$19,449$2,617.14$12,538$822.59+$6.9KCMPI
4$23,835$3,024.07$13,645$956.06+$10.2KCMPI
5$28,967$3,463.51$14,925$1,116.51+$14.0KCMPI
6$34,928$3,933.88$16,415$1,310.57+$18.5KCMPI
7$41,806$4,433.18$18,158$1,546.77+$23.6KCMPI
8$49,692$4,959.03$20,213$1,836.20+$29.5KCMPI
9$58,679$5,508.79$22,649$2,193.37+$36.0KCMPI
10$68,866$6,079.53$25,558$2,637.42+$43.3KCMPI

CMPI vs NNN: Complete Analysis 2026

CMPIStock

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Full CMPI Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this CMPI vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMPI vs SCHDCMPI vs JEPICMPI vs OCMPI vs KOCMPI vs MAINCMPI vs ADCCMPI vs EPRTCMPI vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.